E-mail Print PDF

suPARnostic® - Patient Priority & Prognosis

suPARnostic®’s powerful prognostic value is exhibited in extensive research which shows that high suPAR levels reflect increased inflammation and critical immune activation. suPAR’s high stability and uniform kinetics make it a reliable clinical biomarker.

suPARnostic® acts as a master alarm for a patient’s risk status – an elevated suPARnostic® level reflects a developing critical condition and increased risk of mortality.

General Risk Marker

Various infectious diseases increase suPARnostic® (e.g. sepsis, malaria, etc.).

 triaging_and_monitoring.jpg

predicting_patient_survival.jpg 

suPARnostic®: Certainty in Patient Prognosis and Decision Making

suPARnostic® improves the way patients are managed - an elevated suPARnostic® level is a strong indication of a developing infectious disease or critical condition, a low suPARnostic® level helps avoid time and resources spent on further investigation.

Acute Triaging
suPARnostic® helps identify potentially critical cases early and decide who to treat first - a high suPARnostic® level (5 and above) is indicative of a critical patient condition and increased risk of mortality.

Effective Treatment
suPARnostic® makes it easy to monitor treatment response with one simple blood test - a decreasing suPARnostic® level indicates patient improvement and effective intervention.

 

Last Updated ( Tuesday, 05 May 2009 12:32 )  

News

Great success for the 3´rd International suPAR Symposium in Copenhagen
Read the highlights, news and abstracts....                                                     read_more.jpg

suPAR - the protein that reveals your risk for lifestyle diseases
Read the article in RASK Magasinet .....                                                           read_more.jpg

suPARnostic® partnered with new distributors 
Comercial Rafer in Spain and Portugal, B.S.N. in Italy and Caltag Medsystems in UK....

 

Follow suPAR on Twitter:

 suPARnostic®

suPAR on LinkedIn:

Look for the suPARnostic® group on LinkedIn